Bo Young Oh1, Jung Wook Huh2, Yoon Ah Park1, Yong Beom Cho1, Seong Hyeon Yun1, Hee Cheol Kim1, Woo Yong Lee1, Ho-Kyung Chun3. 1. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. 2. Department of Surgery, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Electronic address: jungwook.huh@gmail.com. 3. Department of Surgery, Kangbuk Samsung Hospital, Sungkyunkwan University School of Medicine, Seoul, Korea.
Abstract
BACKGROUND: The microsatellite instability-high (MSI-H) phenotype of colon cancer has a good prognosis and limited response to chemotherapy. We aimed to investigate prognostic factors and oncologic outcomes in patients with MSI-H sporadic colon cancer. METHODS: A total of 329 patients with MSI-H sporadic colon cancer who underwent radical surgery from January 2004 to December 2012 at a single institution were included. We analyzed prognostic factors and oncologic outcomes according to chemotherapy in these patients compared with patients with MSI-low/microsatellite stable colon cancer. RESULTS: Among the 329 patients, 174 were male and 155 were female. The median age was 59 years. The population consisted of 220 patients with stage II, 97 with stage III, and 12 with stage IV disease. Old age and advanced stage were independent poor prognostic factors of overall survival (OS; P = .014 and P = .040, respectively) and advanced stage and presence of perineural invasion were independent poor prognostic factors of disease-free survival (DFS; P = .004 and P = .001, respectively). In addition, a greater number of poor prognostic factors were associated with worse survival (P < .001). Patients with stage II disease showed no differences in OS and DFS according to receiving or not receiving chemotherapy (P = .140 and P = .694, respectively). CONCLUSION: Old age, advanced stage, and presence of perineural invasion were independent and poor prognostic factors in patients with MSI-H sporadic colon cancer. Survival rates of MSI-H colon cancer patients with stage II disease were not improved by adjuvant chemotherapy.
BACKGROUND: The microsatellite instability-high (MSI-H) phenotype of colon cancer has a good prognosis and limited response to chemotherapy. We aimed to investigate prognostic factors and oncologic outcomes in patients with MSI-H sporadic colon cancer. METHODS: A total of 329 patients with MSI-H sporadic colon cancer who underwent radical surgery from January 2004 to December 2012 at a single institution were included. We analyzed prognostic factors and oncologic outcomes according to chemotherapy in these patients compared with patients with MSI-low/microsatellite stable colon cancer. RESULTS: Among the 329 patients, 174 were male and 155 were female. The median age was 59 years. The population consisted of 220 patients with stage II, 97 with stage III, and 12 with stage IV disease. Old age and advanced stage were independent poor prognostic factors of overall survival (OS; P = .014 and P = .040, respectively) and advanced stage and presence of perineural invasion were independent poor prognostic factors of disease-free survival (DFS; P = .004 and P = .001, respectively). In addition, a greater number of poor prognostic factors were associated with worse survival (P < .001). Patients with stage II disease showed no differences in OS and DFS according to receiving or not receiving chemotherapy (P = .140 and P = .694, respectively). CONCLUSION: Old age, advanced stage, and presence of perineural invasion were independent and poor prognostic factors in patients with MSI-H sporadic colon cancer. Survival rates of MSI-H colon cancerpatients with stage II disease were not improved by adjuvant chemotherapy.
Authors: Patricia E López-Correa; Leonardo S Lino-Silva; Armando Gamboa-Domínguez; César Zepeda-Najar; Rosa A Salcedo-Hernández Journal: J Gastrointest Cancer Date: 2018-09
Authors: Daniel Brungs; Morteza Aghmesheh; Paul de Souza; Weng Ng; Wei Chua; Martin Carolan; Philip Clingan; Emma Healey; June Rose; Tameika Tubaro; Marie Ranson Journal: BMC Cancer Date: 2017-04-08 Impact factor: 4.430
Authors: Elaine Tan; Junmin Whiting; Hao Xie; Iman Imanirad; Estrella Carballido; Seth Felder; Jessica Frakes; Quanxing Mo; Christine Walko; Jennifer B Permuth; Katelyn Sommerer; Richard Kim; Daniel A Anaya; Jason B Fleming; Ibrahim Halil Sahin Journal: Oncologist Date: 2022-03-11